NWRD08 not checked

Newish Biotech (Wuxi) Co., Ltd.

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 2 trial completes
Trials
1 active
2 in total
Targets
 

What this is

How it works
How it works isn't classified yet
How it’s given
“NWRD08 delivered via IM injection + electroporation using TERESA device”In the company’s words, NCT07175662 on ClinicalTrials.gov
Tested for
High-grade Squamous Intraepithelial Lesion (HSIL)
Main trialPhase 2
“This is a randomized, double-blind, placebo controlled Phase 2 study to determine the efficacy and safety of NWRD08 administered by intramuscular (IM) injection followed by electroporation (EP) in adult women with histologically confirmed cervical high grade squamous intraepithelial lesion (HSIL) (cervical intraepithelial neoplasia grade 2 \[CIN2\] or grade 3 \[CIN3\]) associated with human papillomavirus (HPV) 16 and/or HPV18.”In the company’s words, NCT07175662 on ClinicalTrials.gov

Other drugs for High-grade Squamous Intraepithelial Lesion (HSIL)

All 3 drugs for High-grade Squamous Intraepithelial Lesion (HSIL)

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials2

TrialPhaseCompletesWhat it tests
Phase 2Recruiting 30 May 2027 Evaluation of NWRD08 for HPV-16 and/or HPV-18 Related Cervical HSIL
Phase 1Completed 19 Feb 2025 NWRD08 DNA Plasmid for HPV-16 and/or HPV-18 Related Cervical HSIL
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow NWRD08

Following is part of Solo: you see every change to NWRD08 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in